Teladoc Health and Livongo File Definitive Proxy Statement Special Meetings to Be Held on

Teladoc Health and Livongo File Definitive

Special Meetings to Be Held on October

Unanimously Recommend Stockholders Vote

the Merger and Other Proposals Set Forth in the Definitive Proxy Statement

Transaction on Track to Close by End

of Fourth Quarter of 2020

PURCHASE, NY and MOUNTAIN VIEW, Calif., - Sept.

16, 2020 (GLOBE NEWSWIRE) - Teladoc Health (TDOC), the global leader in virtual care, and Livongo (LVGO), the

leading Applied Health Signals company, have filed the definitive joint proxy statement and prospectus with the U.S. Securities

and Exchange Commission in connection with the proposed merger of the two companies. The definitive joint proxy statement and

prospectus is being mailed to all Teladoc Health and Livongo stockholders entitled to vote.

The Teladoc Health Special Meeting of stockholders is scheduled

to take place on October 29, 2020, at 11:00 a.m., Eastern Time, and will be held virtually. All stockholders of record of Teladoc

Health common stock as of the close of business on September 8, 2020, will be entitled to vote at the meeting.

The Livongo Special Meeting of stockholders is scheduled to

take place on October 29, 2020, at 11:00 a.m., Eastern Time, and will be held virtually. All stockholders of record of Livongo

common stock as of the close of business on September 8, 2020, will be entitled to vote at the meeting.

The Teladoc and Livongo Boards of Directors each unanimously

recommends their respective stockholders vote "For" the proposed merger and other proposals set forth in the definitive

joint proxy statement and prospectus. As set forth in the definitive joint proxy statement and prospectus, each share of Livongo

will be exchanged for 0.5920 shares of Teladoc Health plus cash consideration of $4.24. Additionally, prior to the closing of the

merger, Livongo will pay a cash dividend of $7.09 per share of Livongo common stock to stockholders of Livongo as of a record date

immediately prior to closing of the merger.

Together, Teladoc Health and Livongo will provide a consumer

centered virtual care platform for the full spectrum of health needs, creating a new standard in global healthcare delivery, access

and an improved consumer experience. Other highlights of the transaction include:

The combination remains on track to close by the end of the

fourth quarter of 2020, subject to approval by Teladoc Health and Livongo stockholders and other customary closing conditions.

Teladoc Health stockholders who need assistance completing the

proxy card, need additional copies of the proxy materials, or have questions regarding the Teladoc Health Special Meeting may contact

Teladoc Health's proxy solicitors:

MacKenzie Partners, Inc.

Toll-Free: (800) 322-2885

Livongo stockholders who need assistance completing the proxy

card, need additional copies of the proxy materials, or have questions regarding the Livongo Special Meeting may contact Livongo's

Call Collect: (212) 269-5550

Toll Free: (866) 751-6313

About Teladoc Health

Teladoc Health is transforming how people access and experience

healthcare. Recognized as the world leader in virtual care, Teladoc Health directly delivers millions of medical visits across

175 countries each year through the Teladoc Health Medical Group and enables millions of patient and provider interactions for

thousands of hospitals, health systems and physician practices globally. Ranked #1 among direct-to-consumer telehealth providers

in the J.D. Power 2019 U.S. Telehealth Satisfaction Study and Best in KLAS for Virtual Care Platforms for 2020, Teladoc Health

leverages more than a decade of expertise and real-time data insights to meet the growing virtual care needs of consumers, healthcare

professionals, employers and health plans. For more information, please visit teladochealth.com or follow @TeladocHealth on Twitter.

Livongo empowers people with chronic conditions to live better

and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral

health. Livongo pioneered the category of Applied Health Signals to offer Members clinically based insights that focus on the

whole person and make it easier to stay healthy. Using its AI+AI engine, Livongo's team of data scientists aggregate and

interpret substantial amounts of health data and information to create actionable, personalized and timely health signals delivered

to Livongo Members exactly when and where they need them. The Livongo approach delivers better clinical and financial outcomes

while creating a different and better experience for people with chronic conditions. For more information, visit: www.livongo.com or

engage with Livongo on LinkedIn or Twitter.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as

amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally

include statements regarding the potential transaction between Teladoc Health, Inc. ("Teladoc") and Livongo

Health, Inc. ("Livongo"), including any statements regarding the expected timetable for completing the potential

transaction, the ability to complete the potential transaction, the expected benefits of the potential transaction (including

anticipated synergies, projected financial information and future opportunities) and any other statements regarding

Teladoc's and Livongo's future expectations, beliefs, plans, objectives, results of operations, financial

condition and cash flows, or future events or performance. These statements are often, but not always, made through the use

of words or phrases such as "anticipate," "intend," "plan," "believe,"

"project," "estimate," "expect," "may," "should,"

"will" and similar expressions. All such forward-looking statements are based on current expectations of

Teladoc's and Livongo's management and therefore involve estimates and assumptions that are subject to risks,

uncertainties and other factors that could cause actual results to differ materially from the results expressed in the

statements. Key factors that could cause actual results to differ materially from those projected in the forward-looking

statements include the ability to obtain the requisite Teladoc and Livongo stockholder approvals; uncertainties as to the

timing to consummate the potential transaction; the risk that a condition to closing the potential transaction may not be

satisfied; the risk that regulatory approvals (including anticipated tax treatment) are not obtained or are obtained subject

to conditions that are not anticipated by the parties; litigation relating to the potential transaction that have been or

could be instituted against Teladoc, Livongo or their respective directors; the effects of disruption to Teladoc's or

Livongo's respective businesses; restrictions during the pendency of the potential transaction that may impact

Teladoc's or Livongo's ability to pursue certain business opportunities or strategic transactions; the effect of

this communication on Teladoc's or Livongo's stock prices; transaction costs; Teladoc's ability to achieve

the benefits from the proposed transaction; Teladoc's ability to effectively integrate acquired operations into its own

operations; the ability of Teladoc or Livongo to retain and hire key personnel; unknown liabilities; and the diversion of

management time on transaction-related issues. Other important factors that could cause actual results to differ materially

from those in the forward-looking statements include the effects of industry, market, economic, political or regulatory

conditions outside of Teladoc's or Livongo's control (including public health crises, such as pandemics and

epidemics); changes in laws and regulations applicable to Teladoc's business model; changes in market conditions and

receptivity to Teladoc's services and offerings; results of litigation; the loss of one or more key clients of Teladoc

(including potential adverse reactions or changes to business relationships resulting from the announcement or completion of

the potential transaction); changes to Teladoc's abilities to recruit and retain qualified providers into its network;

the impact of the COVID-19 pandemic on the parties' business and general economic conditions; risks regarding

Livongo's ability to retain clients and sell additional solutions to new and existing clients; Livongo's ability

to attract and enroll new members; the growth and success of Livongo's partners and reseller relationships;

Livongo's ability to estimate the size of its target market; uncertainty in the healthcare regulatory environment; and

the factors set forth under the heading "Risk Factors" of Teladoc's Annual Report and Livongo's

Annual Report, in each case on Form 10-K, and in subsequent filings with the U.S. Securities and Exchange Commission (the

"SEC"). These risks, as well as other risks associated with the potential transaction, are more fully discussed

in the joint proxy statement/prospectus filed with the SEC in connection with the proposed transaction. Other unpredictable

or unknown factors not discussed in this communication could also have material adverse effects on forward-looking